Li X, Beeghly-Fadiel A, Bhavnani S, Tavana H, Rubinstein S, Gyawali B
JAMA Netw Open. 2022; 5(4):e224361.
PMID: 35416993
PMC: 9008500.
DOI: 10.1001/jamanetworkopen.2022.4361.
Howard G, Jost T, Yankeelov T, Brock A
PLoS Comput Biol. 2022; 18(3):e1009104.
PMID: 35358172
PMC: 9004764.
DOI: 10.1371/journal.pcbi.1009104.
Hortobagyi G
J Clin Oncol. 2020; 38(21):2454-2462.
PMID: 32255711
PMC: 9798921.
DOI: 10.1200/JCO.20.00199.
Unger J, LeBlanc M, Blanke C
JAMA Oncol. 2017; 3(10):1345-1351.
PMID: 28586789
PMC: 5710507.
DOI: 10.1001/jamaoncol.2017.0762.
Sumetpipat K, Baowan D
J Mol Model. 2014; 20(11):2504.
PMID: 25374391
DOI: 10.1007/s00894-014-2504-1.
Antitumour antibiotic containing regimens for metastatic breast cancer.
Lord S, Ghersi D, Gattellari M, Wortley S, Wilcken N, Simes J
Cochrane Database Syst Rev. 2004; (4):CD003367.
PMID: 15495049
PMC: 6999796.
DOI: 10.1002/14651858.CD003367.pub2.
Cytotoxicity of adriamycin to tumour cells in vivo and in vitro.
Martin W, McNally N
Br J Cancer. 1980; 42(6):881-9.
PMID: 7459222
PMC: 2010572.
DOI: 10.1038/bjc.1980.336.
Chemotherapy of breast cancer.
Perlow L, HOLLAND J
Med Oncol Tumor Pharmacother. 1984; 1(3):169-92.
PMID: 6400037
DOI: 10.1007/BF02934139.
Weekly low dose doxorubicin monotherapy in metastatic breast cancer resistant to previous hormonal and cytostatic treatment.
Scheithauer W, Zielinksi C, Ludwig H
Breast Cancer Res Treat. 1985; 6(1):89-93.
PMID: 4052636
DOI: 10.1007/BF01806014.
Site-dependent response to chemotherapy for carcinoma of the breast.
WHITEHOUSE J
J R Soc Med. 1985; 78 Suppl 9:18-22.
PMID: 4045914
PMC: 1289529.
Mitoxantrone as first-line chemotherapy in advanced breast cancer: results of a collaborative European study.
Mouridsen H, Cornbleet M, Stuart-Harris R, Smith I, Coleman R, Rubens R
Invest New Drugs. 1985; 3(2):139-48.
PMID: 4019118
DOI: 10.1007/BF00174161.
Adriamycin, vinblastine and mitomycin C as second-line chemotherapy in advanced breast cancer.
Sulkes A, Gez E, Pfeffer M, Catane R, Isacson R, BIRAN S
Cancer Chemother Pharmacol. 1986; 18(2):162-7.
PMID: 3791561
DOI: 10.1007/BF00262288.
Studies on the in vivo disposition of adriamycin in human tumours which exhibit different responses to the drug.
Cummings J, McArdle C
Br J Cancer. 1986; 53(6):835-8.
PMID: 3718837
PMC: 2001410.
DOI: 10.1038/bjc.1986.141.
Individual human tumors in short-term micro-organ cultures: chemosensitivity testing by fluorescent cytoprinting.
Rotman B, TEPLITZ C, Dickinson K, Cozzolino J
In Vitro Cell Dev Biol. 1988; 24(11):1137-46.
PMID: 3192508
DOI: 10.1007/BF02620817.
Activity of intravenous menogaril in patients with previously untreated metastatic breast cancer. A National Cancer Institute of Canada Clinical Trials Group study.
Eisenhauer E, Pritchard K, Perrault D, Verma S, Pater J
Invest New Drugs. 1990; 8(3):283-7.
PMID: 2148741
DOI: 10.1007/BF00171838.
Drug treatment of breast cancer.
Davis T, Carbone P
Drugs. 1978; 16(5):441-64.
PMID: 363401
DOI: 10.2165/00003495-197816050-00004.
Sensitivity tests of tumors to cytostatic agents. II. Investigation on human tumors.
Mattern J, Kaufmann M, HINDERER H, Wayss K, Volm M
Z Krebsforsch Klin Onkol Cancer Res Clin Oncol. 1975; 83(2):97-104.
PMID: 124520
DOI: 10.1007/BF00282976.
